U.S. markets closed
  • S&P Futures

    4,222.00
    +12.00 (+0.29%)
     
  • Dow Futures

    33,360.00
    +100.00 (+0.30%)
     
  • Nasdaq Futures

    13,446.00
    +54.00 (+0.40%)
     
  • Russell 2000 Futures

    1,976.30
    +6.80 (+0.35%)
     
  • Crude Oil

    91.80
    -0.13 (-0.14%)
     
  • Gold

    1,802.10
    -11.60 (-0.64%)
     
  • Silver

    20.46
    -0.28 (-1.36%)
     
  • EUR/USD

    1.0292
    -0.0010 (-0.09%)
     
  • 10-Yr Bond

    2.7860
    -0.0110 (-0.39%)
     
  • Vix

    19.74
    -2.03 (-9.32%)
     
  • GBP/USD

    1.2196
    -0.0022 (-0.18%)
     
  • USD/JPY

    133.1340
    +0.2610 (+0.20%)
     
  • BTC-USD

    24,335.06
    +1,416.68 (+6.18%)
     
  • CMC Crypto 200

    573.72
    +42.50 (+8.00%)
     
  • FTSE 100

    7,507.11
    +18.96 (+0.25%)
     
  • Nikkei 225

    27,819.33
    -180.63 (-0.65%)
     

Needham Previews Neurocrine's Upcoming Mid-Stage Data from Essential Tremor Study

  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
·1 min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
  • Needham previews the upcoming Phase 2 data readout for Neurocrine Biosciences Inc's (NASDAQ: NBIX) NBI-827104, a t-type calcium channel blocker in essential tremor (ET), by mid-2022.

  • The analyst notes that though NBI-827104 lags behind its competitors, the market opportunity will be attractive given the total addressable market estimated at ~$13 billion, with no recently approved drugs in ET.

  • The following data readout for Jazz Pharmaceuticals PLC (NASDAQ: JAZZ) and Praxis Precision Medicines Inc's (NASDAQ: PRAX) second Phase 2 trials are expected in 1H of 2024 and 2H of 2022, respectively.

  • Commenting on efficacy, given a similar mechanism of action to Jazz's JZP385 and Praxis' PRAX-944, Needham looks for a change in TETRAS-ADL of 5-6 points and TETRAS-ADL of 4-5 points.

  • TETRAS is designed for the rapid and valid assessment of ET severity.

  • On safety, JZP385 and PRAX-944 both had ~20% discontinuations.

  • The analyst says that if NBI-827104's safety profile can replicate its Phase 1 (~10% discontinuation).

  • Needham expects a single-digit upside to shares on a successful study.

  • Price Action: NBIX shares are up 1.77% at $97.26 during the market session on the last check Monday.

Latest Ratings for NBIX

Date

Firm

Action

From

To

Mar 2022

Piper Sandler

Downgrades

Overweight

Neutral

Feb 2022

Goldman Sachs

Upgrades

Neutral

Buy

Feb 2022

Morgan Stanley

Maintains

Equal-Weight

View More Analyst Ratings for NBIX

View the Latest Analyst Ratings

See more from Benzinga

Don't miss real-time alerts on your stocks - join Benzinga Pro for free! Try the tool that will help you invest smarter, faster, and better.

© 2022 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.